Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Center for Pediatric Clinical Effectiveness Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pediatr Blood Cancer. 2022 Jan;69(1):e29384. doi: 10.1002/pbc.29384. Epub 2021 Oct 28.
The contribution of the gastrointestinal tract microbiome to outcomes after allogeneic hematopoietic cell transplantation (HCT) is increasingly recognized. Investigations of larger pediatric cohorts aimed at defining the microbiome state and associated metabolic patterns pretransplant are needed.
We sought to describe the pretransplant stool microbiome in pediatric allogenic HCT patients at four centers. We performed shotgun metagenomic sequencing and untargeted metabolic profiling on pretransplant stool samples. Samples were compared with normal age-matched controls and by clinical characteristics. We then explored associations between stool microbiome measurements and metabolite concentrations.
We profiled stool samples from 88 pediatric allogeneic HCT patients, a median of 4 days before transplant. Pretransplant stool samples differed from healthy controls based on indices of alpha diversity and in the proportional abundance of specific taxa and bacterial genes. Relative to stool from healthy patients, samples from HCT patients had decreased proportion of Bacteroides, Ruminococcaeae, and genes involved in butyrate production, but were enriched for gammaproteobacterial species. No systematic differences in stool microbiome or metabolomic profiles by age, transplant indication, or hospital were noted. Stool metabolites demonstrated strong correlations with microbiome composition.
Stool samples from pediatric allogeneic HCT patients demonstrate substantial dysbiosis early in the transplant course. As microbiome disruptions associate with adverse transplant outcomes, pediatric-specific analyses examining longitudinal microbiome and metabolome changes are imperative to identify causal associations and to inform rational design of interventions.
越来越多的人认识到胃肠道微生物组对异基因造血细胞移植(HCT)后结局的贡献。需要对更大的儿科队列进行研究,以确定移植前的微生物组状态和相关代谢模式。
我们试图描述四个中心的儿科异基因 HCT 患者移植前的粪便微生物组。我们对移植前的粪便样本进行了 shotgun 宏基因组测序和非靶向代谢物分析。将样本与正常年龄匹配的对照进行比较,并根据临床特征进行比较。然后,我们探讨了粪便微生物组测量值与代谢物浓度之间的相关性。
我们对 88 例儿科异基因 HCT 患者的粪便样本进行了分析,这些患者在移植前中位数为 4 天。移植前的粪便样本与健康对照基于 alpha 多样性指数以及特定分类群和细菌基因的比例丰度存在差异。与健康患者的粪便相比,HCT 患者的粪便中拟杆菌、真杆菌和参与丁酸产生的基因比例降低,但γ变形菌的丰度增加。未观察到粪便微生物组或代谢组谱按年龄、移植适应证或医院的系统差异。粪便代谢物与微生物组组成具有很强的相关性。
儿科异基因 HCT 患者的粪便样本在移植过程的早期就表现出明显的失调。由于微生物组的破坏与不良的移植结果相关,因此需要对儿科患者进行特定的分析,以检查微生物组和代谢组的纵向变化,以确定因果关系,并为干预措施提供合理的设计依据。